- Date and time Tue 28 Apr 2020 from 8:45am to 5:00pm
- Location Royal Society of Medicine
- Organised by Endocrinology and Diabetes
This meeting is a unique opportunity to learn about new strategies to lower cardiovascular risk, heart failure hospitalisation and mortality in type 2 diabetes patients by using novel anti-diabetes agent. Benefits, rational indications and potential side effects will be discussed by experts in the field.
You will hear about the challenges in managing CVD risk, heart failure and renal disease in diabetes and receive an update on recent clinical trials results, focusing on SGLT2 inhibitors and GLP-1 receptor agonists, highlighting these drugs benefits beyond glycaemic control.
We will promote understanding and communication between general practitioners, cardiologists, nephrologists and endocrinologists working together.
- Update on reducing thrombosis risk in diabetes, participants will learn to rationally use novel anti-thrombosis agents in high risk patients.
- Discussing the recent clinical trials results on GLP-1 RAs and SGLT2 inhibitors in Type 2 diabetes highlighting these agents benefits in reducing CVD risk, heart failure and kidney disease. Participants will learn how to use these agents rationally and safely promoting collaboration between endocrinologists, primary care, cardiologists and nephrologists.
|RSM Fellow||RSM Associate||RSM Retired Fellow||RSM Trainee||RSM Student|
Non - Member
|Consultant / GP||AHP / Nurse / Midwife||Trainee||Student|